Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. KYMR
KYMR logo

KYMR News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

KYMR News

Key Wall Street Rating Changes Overview

4d agoCNBC

Kymera Therapeutics Q1 2026 Earnings Call Insights

Apr 30 2026seekingalpha

Kymera Therapeutics Q1 Earnings Announcement Scheduled

Apr 29 2026seekingalpha

Kymera's KT-621 Receives FDA Fast Track Designation

Apr 13 2026NASDAQ.COM

Kymera Therapeutics' KT-621 Receives FDA Fast Track Designation

Apr 13 2026Newsfilter

KYMERA THERAPEUTICS INC - GILEAD TO PROGRESS KT-200 INTO STUDIES PREPARING FOR IND FILING IN 2027

Apr 09 2026moomoo

KYMERA THERAPEUTICS REVEALS GILEAD SCIENCES HAS EXERCISED OPTION TO LICENSE KT-200, AN ORAL CDK2 MOLECULAR GLUE DEGRADER CANDIDATE

Apr 09 2026moomoo

Nextech Reduces Stake in Kymera Therapeutics: Analysis

Mar 19 2026NASDAQ.COM

KYMR Events

No data

No data

KYMR Monitor News

Kymera Therapeutics Reports Strong Q4 Progress and New Partnerships

Feb 26 2026

Kymera Therapeutics Hits 52-Week High on KT-621 Trial Results

Dec 08 2025

KYMR Earnings Analysis

No Data

No Data

People Also Watch